Skip to main content
    C

    Clover Health Investments Corp (CLOV)

    Official site

    HEALTHCARE • HEALTHCARE PLANS • NASDAQ

    $4.73
    -0.22 (-4.44%)

    Market Cap: $2.65B

    Last updated: Nov 17, 2026 at 4:34 PM ET

    Clover Health Investments Corp (CLOV) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Clover Health Investments (CLOV) has a market cap of $2.65B and an enterprise value of $2.38B. Revenue grew 54.50% over the last 12 months from the 12 months before. Its share count is up 3.68% from a year earlier.

    Total Valuation

    Enterprise value is 10.11% below the market cap, as cash exceeds debt.

    Market Cap$2.65B
    Enterprise Value$2.38B
    Latest price (Nov 17, 2026)$4.73

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.41% in the quarter ended Sep 30, 2026 and grew 4.14% a year over 2 years.

    Shares Outstanding531.60M
    Shares Change (YoY)+3.68%
    Shares Change (QoQ)+1.41%
    Share Count Growth (2Y CAGR)+4.14%

    Valuation Ratios

    Sales and book value multiples are 0.9x and 6.4x.

    P/E Ratio118.3x
    Forward P/E80.0x
    P/S Ratio0.9x
    Forward P/S0.9x
    P/B Ratio6.4x
    P/TBV Ratio6.5x
    P/FCF Ratio19.0x
    P/OCF Ratio19.6x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 176.2x EBITDA and 17.0x free cash flow.

    EV / Earnings191.3x
    EV / Sales0.9x
    EV / EBITDA176.2x
    EV / EBIT191.3x
    EV / FCF17.0x

    Price Statistics

    The stock is up 91.50% over 52 weeks and trades 2.16% above its 50-day average.

    Beta (1Y)1.13
    52-Week Change+91.50%
    1-Month Change+6.53%
    3-Month Change+12.09%
    6-Month Change+35.14%
    5-Year Change-40.53%
    Total Return (1Y)+91.50%
    Total Return (3Y CAGR)+66.74%
    Total Return (5Y CAGR)-3.36%
    Return vs SPY (1Y)+89.72%
    Max Drawdown (1Y)-39.50%
    Max Drawdown (3Y)-64.73%
    Sharpe Ratio (1Y)1.21
    Correlation with SPY (1Y)0.27
    50-Day Average$4.63
    200-Day Average$3.68
    52-Week Range$1.58 to $5.59
    RSI (14 Days)50.8
    Average Volume (20 Days)4.65M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Returns and Efficiency

    Return on equity is 3.19% over the last 12 months, against a 5-year average of -63.95%.

    Return on Equity (ROE)3.19%
    Return on Assets (ROA)1.65%
    ROE (5Y Average)-63.95%
    ROA (5Y Average)-32.88%
    ROIC (5Y Average)-51.94%
    Asset Turnover4.17x

    Scores

    CLOV has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $2.74B over the last 12 months.

    Revenue$2.74B
    Revenue Growth (YoY)+54.50%
    Pretax Income$12.45M
    Net Income$12.45M
    EBITDA$12.75M
    EBIT$12.45M
    Reported EPS (TTM)$0.04

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 51.86% of the $753.68M in total assets.

    Cash and Equivalents$268.07M
    Total Debt$0
    Net Cash$268.07M
    Net Cash Per Share$0.50
    Shareholder Equity$390.87M
    Book Value Per Share$0.74
    Tangible Book Value$387.88M
    Tangible Book Per Share$0.73
    Total Assets$753.68M
    Total Liabilities$362.81M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $3.03M of capital spending, operating cash flow left $132.28M of free cash flow.

    Operating Cash Flow$135.31M
    Capital Expenditures$3.03M
    Free Cash Flow$132.28M
    FCF Per Share$0.30
    Depreciation and Amortization$459.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    Pretax Margin0.45%
    Net Margin0.45%
    EBITDA Margin0.47%
    EBIT Margin0.45%
    FCF Margin4.83%
    Gross Margin (5Y Average)13.89%
    Operating Margin (5Y Average)-18.69%
    Net Margin (5Y Average)-19.06%

    Growth

    Revenue grew 20.28% a year over 3 years.

    Revenue Growth (3Y CAGR)+20.28%
    Revenue Growth (5Y CAGR)+21.37%
    Book Value Per Share Growth (2Y CAGR)+0.18%
    Tangible Book Per Share Growth (2Y CAGR)+0.22%

    Revenue and profit by year

    Dividends and Yields

    CLOV does not pay a dividend. Its free cash flow yield is 5.26%.

    Earnings Yield0.85%
    FCF Yield5.26%
    Buyback Yield-0.18%
    Shareholder Yield-0.18%

    Peer Position

    Against 12 similar companies, CLOV has the highest P/E and the 6th highest P/S.

    P/E Ratio118.3x vs 28.5x median
    P/S Ratio0.9x vs 0.6x median
    Revenue Growth (Trailing 4 Quarters, YoY)+54.50% vs +6.16% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 37.99% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+37.99%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CLOV

    What is CLOV's market cap?

    Clover Health Investments has a market cap of $2.65B. Its enterprise value, which adds debt and subtracts cash, is $2.38B.

    What is CLOV's P/E ratio?

    Clover Health Investments has a trailing P/E ratio of 118.3x and a forward P/E of 80.0x.

    How many shares of CLOV are outstanding?

    Clover Health Investments has 531.60M shares outstanding. The count is up 3.68% from a year earlier.

    Does CLOV pay a dividend?

    No. Clover Health Investments does not pay a dividend.

    How much debt does CLOV have?

    Clover Health Investments has $0 of total debt and $268.07M of cash and equivalents, a net cash position of $268.07M.